Saturday's attack is the biggest on Saudi oil infrastructure since Saddam Hussein's invasion of Kuwait in 1990.Energyread more
Saudi Aramco is aiming to restore by Monday about a third of its crude output that was disrupted after drone attacks on two key oil facilities, The Wall Street Journal...Marketsread more
"Blaming Iran won't end disaster. Accepting our April '15 proposal to end war & begin talks may," Zarif said on Twitter.Energyread more
Oil prices are expected to jump as much as $10 per barrel after a coordinated drone strike hit Saudi Arabia's largest oil field, forcing the kingdom to cut its oil output in...Marketsread more
Apple's new iPhones can still send texts, download apps, and make video calls, but the company spends a lot of time and effort marketing its new phones as powerful photography...Technologyread more
The trucking industry is worth hundreds of billions of dollars per year. Uber is going after this market with Uber Freight, an online platform that matches truckers with...Technologyread more
Some U.S. manufacturers say tariffs, if targeted, will help address longstanding unfair trade practices like intellectual property theft.Traderead more
Supporters of a $15 minimum wage ballot initiative in Florida argue the state's inflation-tied pay hikes have not gone far enough.2020 Electionsread more
Saudi Arabia shut down half its oil production Saturday after drone strikes hit the world's largest oil processing facility in an attack claimed by Yemen's Houthi rebels.Politicsread more
Trusii's hydrogen water machines were supposed to help users with their health problems, but customers claim the company is involved in a giant scam.Technologyread more
The decoupling of the world's two weightiest economies seems as inescapable as its extent and global impact remains incalculable.Politicsread more
Several hundred hospitals that plan to form their own generic drug company are eyeing making "about 20" pharmaceutical products whose existing versions either cost too much or are in short supply for no good reason, the CEO of one of those hospitals said Thursday.
Dr. Marc Harrison, chief of Utah-based Intermountain Healthcare, during an interview on CNBC's "Closing Bell," would not identify the existing drugs that the new company wants to replicate on its own, or have done on a contract basis.
Harrison said, "We think it will be early '19 before our first drugs come to market."
And he said the group also is hoping to possibly get additional financing from "philanthropists who are sick of this activity" by drug companies that is "creating shortages and driving prices in an irrational fashion."
Intermountain is leading the collaboration with several other large hospital groups, Ascension, SSM Health and Trinity Health, in consultation with the U.S. Department of Veterans Affairs, to form a not-for-profit drug company. The groups together represent more than 450 U.S. hospitals.
Harrison said on "Closing Bell" that the project was spurred by feedback by patients who at times were saying "they can't get ahold of drugs or they're way too expensive."
"We're experiencing that in the hospital as well, and we've been thinking about this for a couple of years now," Harrison said.
"We worked hard to come up with a plan ... now is the time to get to work."
He said that one of the big problems in the pharmaceuticals market today is that some "individuals and groups have gone ahead and gotten sole control over a given drug."
"They create shortages and drive the prices up, and our patients can't get ahold of the drugs we need," Harrison said.
"We as a team will do the opposite," he said. "We'll make sure drugs are available in good quantities and reasonable prices."
Harrison said the members of the consortium will contribute funds to finance the new drug company.
"Over time, the business plan says we'll get our money back," he said.
Harrison also said that he expects the new firm to provide just a small fraction of pharmaceutical products that the hospitals have to purchase.
"We expect that the vast majority of drugs we buy will still come in the same channels we have always gotten them," he said. "We think most pharmacies are doing a great job and drug manufacturers are doing a great job."
"We're only interested in those organizations that are creating shortages and driving drug prices up in an irrational fashion," Harrison said.